20 Years of Research and 10,000 Patients: Ora Dry Eye System Supports Two Largest Exits in Dry Eye

27-11-2013 Business Wire HealthComments (0)

OphthalmicsOraPharmaPharmaceutical

Related Companies

Ora, Inc., the world’s leading independent, full-service ophthalmic contract research organization (CRO) and product development firm, announced today its support of two dry eye exits in 2013 valuing in excess of a billion dollars for its clients. In July, the global eye health company Bausch + Lomb announced that it acquired an option to license Mimetogen’s MIM-D3, an investigational compound currently in phase III development for the treatment of dry eye. Mos

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top